Cingulate Inc. (CING)
Cingulate Inc. (CING) Stock Price, Analysis & Data
| Бид | 3.75 |
| Рыночная капитализация | 76.64M |
| Выручка (TTM) | n/a |
| Чистая прибыль (TTM) | -28.8M |
| Бета | n/a |
| EPS (TTM) | -3.56 |
| P/E (TTM) | n/a |
| Прогнозный P/E | -7.12 |
| P/B (TTM) | 15.23 |
| P/S (TTM) | n/a |
| Earnings Date | n/a |
| Аск | 6.5 |
| Объём торгов | 72,914 |
| Ср. объём (20д) | 429,253 |
| Открытие | 5.15 |
| Пред. закрытие | 5.20 |
| Диапазон дня | 5.01 - 5.25 |
| Диапазон за 52 недели | 3.16 - 11.89 |
| Аналитики | n/a |
| Целевая цена | n/a |
| Дивиденды | n/a |
| Дата отсечки | n/a |
О компании CING
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a f...
Финансовые результаты
В 2025 году выручка Cingulate составила 0 — это рост на undefined% к прошлогодним 0. Прибыль составила -22.45M — это рост на 35.57%.
Финансовая отчётностьСюрприз в отчёте
3 месяцев назад · Insider Monkey
Here is Why Cingulate (CING) is One of the Best NASDAQ Growth Stocks to Buy and Hold ForeverCingulate Inc. (NASDAQ:CING) is one of the best NASDAQ growth stocks to buy and hold forever. On March 18, Cingulate reported its financial results for Q4 and the full year 2025, highlighting the rece...
